Artelo Biosciences Inc Stock Price, News & Analysis

Artelo Biosciences (ARTL) has completed enrollment in the final cohort of its Phase 1b Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at evaluating safety and efficacy in cancer patients experiencing anorexia. The highest permissible dose of 650 micrograms has been administered, with preliminary results indicating a well-tolerated safety profile and mild adverse reactions. The company anticipates progressing to the randomized Phase 2a stage to assess the drug's effectiveness, targeting a market projected to exceed $2 billion for cancer-related appetite loss treatments. Artelo expresses gratitude to participants and research teams for overcoming enrollment challenges.

Artelo Biosciences, a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the Sequire Biotechnology Conference on February 2, 2023, at 1:00 PM ET. The presentation will focus on the Company’s ongoing Cancer Appetite Recovery Study (CAReS). The biotechnology sector is projected to reach $727 billion by 2025, highlighting its growth potential. This event, hosted virtually, aims to connect public biotech companies with investors. Artelo is dedicated to developing innovative treatments targeting significant unmet needs related to cancer and other conditions. More details can be found at artelobio.com.

Artelo Biosciences (Nasdaq: ARTL) reported financial results for the quarter ending September 30, 2022, showing a net loss of approximately $2.3 million, or $0.82 per share, compared to a loss of $2.2 million or $1.37 per share for the same period in 2021. As of September 30, 2022, the company had $19.5 million in cash and investments, expected to support operations through mid-2024. Enrollment for the Phase 2a Cancer Appetite Recovery Study (CAReS) is set to begin near year-end, following positive Phase 1b results.

Artelo also highlighted promising non-clinical data for its FABP5 platform, indicating potential treatments for both pain and anxiety.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29, 2022, in New York City. CEO Gregory D. Gorgas will speak at 8:30 a.m. ET, and one-on-one meetings will be available throughout the event. The presentation will also be streamed online. Artelo focuses on developing treatments for cancer, pain, and neurological conditions through lipid-signaling pathways, aiming to address significant unmet medical needs.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The event includes virtual and in-person attendance at the Lotte New York Palace Hotel. The presentation will be available on-demand starting September 12 at 7:00 AM ET. Artelo focuses on developing treatments for cancer, pain, and neurological conditions through lipid-signaling pathway modulation.

Artelo Biosciences (ARTL) recently announced pre-clinical findings suggesting that its fatty acid binding protein 5 (FABP5) inhibitor may effectively reduce anxiety behaviors in key brain areas. These results indicate that FABP5 modulation could serve as a new target for developing anxiety treatments, including potential therapies for post-traumatic stress disorder (PTSD). Published in Cerebral Cortex, the study led by researchers from the University of Western Ontario demonstrates the role of the CB₂ receptor in managing fear and anxiety, underscoring the importance of this research.

Artelo Biosciences (Nasdaq: ARTL) announced advancements in its clinical programs with the CAReS Study for ART27.13, targeting cancer-related anorexia, progressing to a fourth cohort due to its well-tolerated safety profile. The company also reported a net loss of $2.4 million for Q2 2022 and a cash balance of $21.3 million, expected to fund operations into 2023. A 15-for-1 reverse stock split will take effect on August 10, 2022, aimed at enhancing stock marketability and compliance with Nasdaq requirements.

Artelo Biosciences (Nasdaq: ARTL) has initiated the fourth cohort at a 650-microgram dose in its Cancer Appetite Recovery Study (CAReS) for ART27.13, following successful completion of the first three cohorts. The safety review committee reported that ART27.13 was well-tolerated, with no serious adverse events linked to the drug. The Phase 1b trial will help determine the optimal dose before transitioning to a Phase 2a study. ART27.13 targets cannabinoid receptors to address cancer-related anorexia, tapping into a market exceeding $2 billion annually.

Artelo Biosciences (Nasdaq: ARTL) recently presented research at the ICRS Symposium highlighting the effectiveness of its lead compound, ART26.12, in managing chemotherapy-induced pain. Professor Saoirse O’Sullivan reported that ART26.12 demonstrated significant effectiveness in preventing and treating pain sensitivity without sedation, while also mitigating weight loss linked to chemotherapy. The company aims to pursue FDA consultations for ART26.12’s further development. This research opens potential pathways for addressing Chemotherapy-Induced Peripheral Neuropathy, a condition without approved therapies.